Cellectar Biosciences Inc (CLRB)
Cellectar Biosciences Inc (CLRB) is a NASDAQ-listed biotechnology company in the healthcare sector. The company security is common stock, meaning it is a common equity instrument tied to ownership in the business rather than a fund, note, or other security type. Cellectar Biosciences focuses on developing cancer-related therapies and research programs within clinical biopharmaceutical work. Its business is centered on oncology-focused drug development and related scientific efforts, with an emphasis on targeted approaches to treatment. Investors should view CLRB as an operating company security linked to a biotechnology issuer and its research pipeline, not as a fixed-income or pooled investment product.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CLRB
|
$3.17
|
42.2% Upside
|
Undervalued
|
$11.50
|
415.7% Upside
|
Bargain
|
Fair
|
0.0%
|
October 29, 2026
|
0.7x
|
21.078 M
|
-11.384 M
|
6.8%
|
98.2%
|
-16.2
|
87.3%
|
